European Journal of Pediatrics

, Volume 167, Issue 1, pp 47–55 | Cite as

Varicella vaccination in Europe: are we ready for a universal childhood programme?

  • Nitu Sengupta
  • Robert Booy
  • H. J. Schmitt
  • Heikki Peltola
  • Pierre Van-Damme
  • R. Fabian Schumacher
  • Magda Campins
  • Carlos Rodrigo
  • Terho Heikkinen
  • Jane Seward
  • Aisha Jumaan
  • Adam Finn
  • Per Olcén
  • Nancy Thiry
  • Catherine Weil-Olivier
  • Judith Breuer
Original Paper

Abstract

Safe and effective vaccines against varicella zoster virus (VZV), the aetiological agent of varicella and shingles, have been available in Europe for the last 5–10 years. The USA has had a universal childhood vaccination policy since 1995 and this has resulted in a dramatic decrease in the incidence, morbidity and mortality related to varicella. The economic and medical burden of VZV has led to discussions regarding both the desirability and feasability of a similar routine immunisation policy for all European children. This article examines the epidemiology of varicella in Europe and how the data emerging from the USA can be used to achieve adequate prevention of the disease. It looks into the current evidence of the health economic evaluation of universal varicella vaccination and explores the concerns surrounding such a policy, including the postulated impact on the incidence of zoster. In conclusion, the Society of Independent European Vaccination Experts (SIEVE) recommends that the immunisation of susceptible adolescents needs to be urgently implemented, in addition to the current recommendations targeting high-risk patients, their close contacts with a negative history of varicella and seronegative health-care workers. A universal policy, optimally incorporating a two-dose schedule, will be needed to finally reduce the burden of disease of varicella from a societal point of view. The SIEVE recommends the implementation of such a policy as soon as financially and practically possible.

Keywords

Varicella Vaccination Chickenpox Zoster Herpes zoster Shingles 

Notes

Acknowledgements

This Society of Independent European Vaccination Experts (SIEVE) report was made possible by an unrestricted grant from the Stiftung Präventive Pädiatrie at Johannes-Gutenberg-Universität, Mainz, Germany.

Conflict of interest statement

Financial disclosures:
  • Robert Booy: On occasions I am provided support by vaccine companies to attend/present at scientific meetings, including CSL, Sanofi, GSK, Roche & Wyeth. If fees are offered to me, I direct them to a University research account.

  • Judy Breuer: JB has received funding for work on VZV and for attendance at meetings from SPMSD, Merck, GSK.

  • Magda Campins: Research Grants (GlaxoSmithKline), Consultant/Lecture fees (GlaxoSmithKline, Laboratories Esteve, Wyeth Farma SA).

  • Adam Finn: AF has undertaken clinical trials research, paid consultancy and spoken at meetings organised by SanofiPasteur-MSD and GSK who manufacture varicella vaccines. All payments related to these activities have been made to his employer the University of Bristol.

  • Terho Heikkinen: No conflicts declared.

  • Aisha Jumaan: I have no conflicts of interest.

  • Per Olcen: No conflicts of interest declared.

  • Heikki Peltola: Although the undersigned has received speaker fees, been sponsored to scientific meetings by various companies, and is consulting Serum Institute of India. Ltd., none of these advantages is relevant to his analysis of varicella vaccines.

  • Carlos Rodrigo: I have no conflict of interest.

  • Joe Schmitt: I have no financial interest in any vaccine manufacturer. I have been conducting studies for all major vaccine producers, including Sanofi Pasteur MSD and GSK, who both produce varicella vaccine. I have also participated in various advisory boards and I am employed by the local government.

  • Fabian Schumacher: No conflict of interest.

  • Nitu Sengupta: NS has received funds from Sanofi Pasteur MSD to attend symposia in the past.

  • Jane Seward: I have no conflict of interest.

  • Nancy Thiry: I have no conflict of interest to declare.

  • Jean-Piere van Damme: PVD has been principal investigator of vaccine trials for Merck, Sanofi Pasteur MSD, Sanofi Pasteur, Wyeth and GlaxoSmithKline Biologicals for which the University of Antwerp receives research grants. None of these trials were related to varicella vaccines in the last 5 years.

  • Catherine Weil-Oliver: I certify the absence of any possible conflicts of interest in the varicella vaccination field. I accept all conditions from Prof. Schmitt and other authors for the publication of the paper on this topic.

References

  1. 1.
    Aebi C, Fischer K, Gorgievski M, Matter L, Muhlemann K (2001) Age-specific seroprevalence to varicella-zoster virus: study in Swiss children and analysis of European data. Vaccine 19(23–24):3097–3103PubMedCrossRefGoogle Scholar
  2. 2.
    Arbeter AM, Starr SE, Preblud SR, Ihara T, Paciorek PM, Miller DS, Zelson CM, Proctor EA, Plotkin SA (1984) Varicella vaccine trials in healthy children. A summary of comparative and follow-up studies. Am J Dis Child 138(5):434–438PubMedGoogle Scholar
  3. 3.
    Arvin A, Gershon A (2006) Control of varicella: why is a two-dose schedule necessary? Pediatr Infect Dis J 25(6):475–476PubMedCrossRefGoogle Scholar
  4. 4.
    Banz K, Wagenpfeil S, Neiss A, Goertz A, Staginnus U, Vollmar J, Wutzler P (2003) The cost-effectiveness of routine childhood varicella vaccination in Germany. Vaccine 21(11–12):1256–1267PubMedCrossRefGoogle Scholar
  5. 5.
    Barrett-Muir W, Scott FT, Aaby P, John J, Matondo P, Chaudhry QL, Siqueira M, Poulsen A, Yaminishi K, Breuer J (2003) Genetic variation of varicella-zoster virus: evidence for geographical separation of strains. J Med Virol 70(Suppl 1):S42–S47PubMedCrossRefGoogle Scholar
  6. 6.
    Boelle PY, Hanslik T (2002) Varicella in non-immune persons: incidence, hospitalization and mortality rates. Epidemiol Infect 129(3):599–606PubMedCrossRefGoogle Scholar
  7. 7.
    Bramley JC, Jones IG (1981) Epidemiology of chickenpox in Scotland: 1981 to 1998. Commun Dis Public Health 3(4):282–287Google Scholar
  8. 8.
    Breuer J (2005) Varicella vaccination for healthcare workers. BMJ 330(7489):433–434PubMedCrossRefGoogle Scholar
  9. 9.
    Brisson M, Edmunds WJ (2003) Varicella vaccination in England and Wales: cost-utility analysis. Arch Dis Child 88(10):862–869PubMedCrossRefGoogle Scholar
  10. 10.
    Brisson M, Edmunds WJ, Law B, Gay NJ, Walld R, Brownell M, Roos L, De Serres G (2001) Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 127(2):305–314PubMedCrossRefGoogle Scholar
  11. 11.
    Brisson M, Gay NJ, Edmunds WJ, Andrews NJ (2002) Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 20(19–20):2500–2507PubMedCrossRefGoogle Scholar
  12. 12.
    Brisson M, Edmunds WJ, Gay NJ, Law B, De Serres G (2000) Analysis of varicella vaccine breakthrough rates: implications for the effectiveness of immunisation programmes. Vaccine 18(25):2775–2778PubMedCrossRefGoogle Scholar
  13. 13.
    Broussard RC, Payne DK, George RB (1991) Treatment with acyclovir of varicella pneumonia in pregnancy. Chest 99(4):1045–1047PubMedCrossRefGoogle Scholar
  14. 14.
    Cameron JC, Allan G, Johnston F, Booy R, Heath PT, Finn A (2005) Severe complications of chickenpox in hospitalised children. Arch Dis Child 90(Suppl II):A1Google Scholar
  15. 15.
    [No authors listed] (1984) Varicella-zoster immune globulin for the prevention of chickenpox. Recommendations of the Immunization Practices Advisory Committee, Centers for Disease Control. Ann Intern Med 100(6):859–865Google Scholar
  16. 16.
    CDC (2005) Notice to readers: licensure of a combined live attenuated measles, mumps, rubella, and varicella vaccine. Available online at http://www.cdc.gov/MMWR/preview/mmwrhtml/mm5447a4.htm
  17. 17.
    Ciofi degli Atti ML, Rota MC, Mandolini D, Bella A, Gabutti G, Crovari P, Salmaso S (2002) Assessment of varicella underreporting in Italy. Epidemiol Infect 128(3):479–484PubMedCrossRefGoogle Scholar
  18. 18.
    Coudeville L, Paree F, Lebrun T, Sailly J (1999) The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 17(2):142–151PubMedCrossRefGoogle Scholar
  19. 19.
    Davis MM, Gaglia MA (2005) Associations of daycare and school entry vaccination requirements with varicella immunization rates. Vaccine 23(23):3053–3060PubMedCrossRefGoogle Scholar
  20. 20.
    Davis MM, Patel MS, Gebremariam A (2004) Decline in varicella-related hospitalizations and expenditures for children and adults after introduction of varicella vaccine in the United States. Pediatrics 114(3):786–792PubMedCrossRefGoogle Scholar
  21. 21.
    Department of Health (2006) Pneumoccocal vaccine added to the childhood immunisation programme: more protection against meningitis and septicaemia. Available online at http://www.immunisation.nhs.uk/newsitem.php?id=56
  22. 22.
    Diez Domingo J, Ridao M, Latour J, Ballester A, Morant A (1999) A cost benefit analysis of routine varicella vaccination in Spain. Vaccine 17(11–12):1306–1311PubMedCrossRefGoogle Scholar
  23. 23.
    Enders G, Miller E, Cradock-Watson J, Bolley I, Ridehalgh M (1994) Consequences of varicella and herpes zoster in pregnancy: prospective study of 1739 cases. Lancet 343(8912):1548–1551PubMedCrossRefGoogle Scholar
  24. 24.
    ESPED Study Group (2006) Varicella zoster virus infection. Hospitalisations and complications in children and adolescents, Germany 2003–2004. Final Report 2006Google Scholar
  25. 25.
    Feldman S, Hughes WT, Daniel CB (1975) Varicella in children with cancer: seventy-seven cases. Pediatrics 56(3):388–397PubMedGoogle Scholar
  26. 26.
    Feldman S, Lott L (1987) Varicella in children with cancer: impact of antiviral therapy and prophylaxis. Pediatrics 80(4):465–472PubMedGoogle Scholar
  27. 27.
    Gabutti G, Penna C, Rossi M, Salmaso S, Rota MC, Bella A, Crovari P; Serological Study group (2001) The seroepidemiology of varicella in Italy. Epidemiol Infect 126(3):433–440PubMedCrossRefGoogle Scholar
  28. 28.
    Galil K, Lee B, Strine T, Carraher C, Baughman AL, Eaton M, Montero J, Seward J (2002) Outbreak of varicella at a day-care center despite vaccination. N Engl J Med 347(24):1909–1915PubMedCrossRefGoogle Scholar
  29. 29.
    Gershon AA (2002) Varicella vaccine—are two doses better than one? N Engl J Med 347(24):1962–1963PubMedCrossRefGoogle Scholar
  30. 30.
    Gershon AA, LaRussa P, Steinberg S (1996) The varicella vaccine. Clinical trials in immunocompromised individuals. Infect Dis Clin North Am 10(3):583–594PubMedCrossRefGoogle Scholar
  31. 31.
    Gil A, San-Martin M, Carrasco P, Gonxalez A (2004) Epidemiology of severe varicella-zoster virus infection in Spain. Vaccine 22(29–30):3947–3951PubMedCrossRefGoogle Scholar
  32. 32.
    Harel Z, Ipp L, Riggs S, Vaz R, Flanagan P (2001) Serotesting versus presumptive varicella vaccination of adolescents with a negative or uncertain history of chickenpox. J Adolesc Health 28(1):26–29PubMedCrossRefGoogle Scholar
  33. 33.
    Heininger U (2002) The utility of serologic testing for varicella in an adolescent population. Vaccine 20(11–12):1480PubMedCrossRefGoogle Scholar
  34. 34.
    Hope-Simpson RE (1965) The nature of herpes zoster: a long-term study and a new hypothesis. Proc R Soc Lond 58:9–20Google Scholar
  35. 35.
    Health Protection Agency (HPA) (2006) General information—chickenpox (varicella). Available online at http://www.hpa.org.uk/infections/topics_az/chickenpox/gen_info.htm
  36. 36.
    Jaeggi A, Zurbruegg RP, Aebi C (1998) Complications of varicella in a defined central European population. Arch Dis Child 79(6):472–477PubMedCrossRefGoogle Scholar
  37. 37.
    Kanra G, Tezcan S, Badur S; Turkish National Study Team (2002) Varicella seroprevalence in a random sample of the Turkish population. Vaccine 20(9–10):1425–1428PubMedCrossRefGoogle Scholar
  38. 38.
    Kilgore PE, Kruszon-Moran D, Seward JF, Jumaan A, Van Loon FP, Forghani B, McQuillan GM, Wharton M, Fehrs LJ, Cossen CK, Hadler SC (2003) Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol 70(Suppl 1):S111–S118PubMedCrossRefGoogle Scholar
  39. 39.
    Knuf M, Habermehl P, Zepp F, Manhardt W, Kuttnig MK, Muttoneen P, Prieler A, Maurer H, Bisanz H, Tornieporth N, Descamps D, Willems P (2006) Immunogenicity and safety of two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children. Ped Infect Dis J 25(1):12–18CrossRefGoogle Scholar
  40. 40.
    Kudesia G, Partridge S, Farrington CP, Soltanpoor N (2002) Changes in age related seroprevalence of antibody to varicella zoster virus: impact on vaccine strategy. J Clin Pathol 55(2):154–155PubMedGoogle Scholar
  41. 41.
    Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I;Study Group for Varivax (2004) Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23(2):132–137PubMedCrossRefGoogle Scholar
  42. 42.
    Kuter BJ, Ngai A, Patterson CM, Staehle BO, Cho I, Matthews H, Provost PJ, White CJ (1995) Safety, tolerability, and immunogenicity of two regimens of Oka/Merck varicella vaccine (Varivax) in healthy adolescents and adults. Oka/Merck Varicella Vaccine Study Group. Vaccine 13(11):967–972PubMedCrossRefGoogle Scholar
  43. 43.
    Lee BR, Feaver SL, Miller CA, Hedberg CW, Ehresmann KR (2004) An elementary school outbreak of varicella attributed to vaccine failure: policy implications. J Infect Dis 190(3):477–483PubMedCrossRefGoogle Scholar
  44. 44.
    Loparev VN, Gonzalez A, Deleon-Carnes M, Tipples G, Fickenscher H, Torfason EG, Schmid DS (2004) Global identification of three major genotypes of varicella-zoster virus: longitudinal clustering and strategies for genotyping. J Virol 78(15):8349–8358PubMedCrossRefGoogle Scholar
  45. 45.
    MacIntyre CR, Chu CP, Burgess MA (2003) Use of hospitalization and pharmaceutical prescribing data to compare the prevaccination burden of varicella and herpes zoster in Australia. Epidemiol Infect 131(1):675–682PubMedCrossRefGoogle Scholar
  46. 46.
    Meyer PA, Seward JF, Jumaan AO, Wharton M (2000) Varicella mortality: trends before vaccine licensure in the United States, 1970–1994. J Infect Dis 182(2):383–390PubMedCrossRefGoogle Scholar
  47. 47.
    Miller E, Cradock-Watson JE, Ridehalgh MK (1989) Outcome in newborn babies given anti-varicella-zoster immunoglobulin after perinatal maternal infection with varicella-zoster virus. Lancet 2(8659):371–373PubMedCrossRefGoogle Scholar
  48. 48.
    Nguyen HQ, Jumaan AO, Seward JF (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352(5):450–458PubMedCrossRefGoogle Scholar
  49. 49.
    [No authors listed] (2003) Varivax [Varicella Virus Vaccine Live (Oka/Merck)]. Available online at http://www.merck.com/product/usa/pi_circulars/v/varivax/varivax-pi-pdf. 10-6-2003. Ref Type: Generic
  50. 50.
    [No authors listed] (2003) Varilrix. Summary of product characteristics. Available online at http://www.healthprotection.org.uk/communicable/varilix.pdf. 2003. Ref Type: Generic
  51. 51.
    Office of Standards and Education (2003) Registered childcare providers and places in England, 31 March 2003. Office of Standards and Education (Ofsted) publication. Available online at http://www.ofsted.gov.uk/assets/3411.pdf
  52. 52.
    Piano Nazionale Vaccini 2005–2007. Available online at http://www.ministerosalute.it/promozione/malattie/sezMalattie.jsp?id=15&label=vac
  53. 53.
    Pinot de Moira A, Nardone A; ESEN2 Group (2005) Varicella zoster virus vaccination policies and surveillance strategies in Europe. Euro Surveill 10(1):43–44PubMedGoogle Scholar
  54. 54.
    Quinlivan M, Hawrami K, Barrett-Muir W, Aaby P, Arvin A, Chow VT, John JT, Matondo P, Peiris M, Pulsen A, Siqueira M, Takahashi M, Talukder Y, Yamanishi K, Leedham-Green M, Scott FT, Thomas SL, Breuer J (2002) The molecular epidemiology of varicella zoster virus: evidence for geographical segregation. J Infect Dis 186(7):888–894PubMedCrossRefGoogle Scholar
  55. 55.
    Rasch G, Hellenbrand W (2004) Germany adds varicella vaccine to the national vaccination programme. Euro Surveill 8(31):1–2Google Scholar
  56. 56.
    Rawson H, Crampin A, Noah N (2001) Deaths from chickenpox in England and Wales 1995-7: analysis of routine mortality data. BMJ 323(7321):1091–1093PubMedCrossRefGoogle Scholar
  57. 57.
    Ronan K, Wallace MR (2001) The utility of serologic testing for varicella in an adolescent population. Vaccine 19(32):4700–4702PubMedCrossRefGoogle Scholar
  58. 58.
    Salleras L, Dominguez A, Vidal J, Plans P, Salleras M, Taberner JL (2000) Seroepidemiology of varicella-zoster virus infection in Catalonia (Spain). Rationale for universal vaccination programmes. Vaccine 19(2–3):183–188PubMedCrossRefGoogle Scholar
  59. 59.
    Schmitt HJ, Booy R, Weil-Olivier C, Van Damme P, Cohen R, Peltola H (2003) Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis 3(2):103–108PubMedCrossRefGoogle Scholar
  60. 60.
    Seward JF, Watson BM, Peterson CL, Mascola L, Pelosi JW, Zhang JX, Maupin TJ, Goldman GS, Tabony LJ, Brodovicz KG, Jumaan AO, Wharton M (2002) Varicella disease after introduction of varicella vaccine in the United States, 1995–2000. JAMA 287(5):606–611PubMedCrossRefGoogle Scholar
  61. 61.
    Sharrar RG, LaRussa P, Galea SA, Steinberg SP, Sweet AR, Keatley RM, Wells ME, Stephenson WP, Gershon AA (2000) The postmarketing safety profile of varicella vaccine. Vaccine 19(7–8):916–923PubMedCrossRefGoogle Scholar
  62. 62.
    Shinefeld H, Black S, Digilio L, Reisinger K, Blatter M, Gress JO, Brown H, Eves KA, Klopfer SO, Schodel F, Kuter BJ (2005) Evaluation of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children. Ped Infect Dis J 24(8):665–669CrossRefGoogle Scholar
  63. 63.
    Snoeck R, Andrei G, De Clercq E (1999) Current pharmacological approaches to the therapy of varicella zoster virus infections: a guide to treatment. Drugs 57(2):187–206PubMedCrossRefGoogle Scholar
  64. 64.
    Stankus SJ, Dlugopolski M, Packer D (2000) Management of herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician 61(8):2437–2438PubMedGoogle Scholar
  65. 65.
    Terada K, Hiraga Y, Kawano S, Kataoka N (1995) Incidence of herpes zoster in pediatricians and history of reexposure to varicella-zoster virus in patients with herpes zoster (in Japanese). Kansenshogaku Zasshi 69(8):908–912PubMedGoogle Scholar
  66. 66.
    Thiry N, Beutels P, Shkedy Z, Vranckx R, Vandermeulen C, Wielen MV, Damme PV (2002) The seroepidemiology of primary varicella-zoster virus infection in Flanders (Belgium). Eur J Pediatr 161(11):588–593PubMedCrossRefGoogle Scholar
  67. 67.
    Thiry N, Beutels P, Van Damme P, Van Doorslaer E (2003) Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21(1):13–38PubMedCrossRefGoogle Scholar
  68. 68.
    Thomas SL, Wheeler JG, Hall AJ (2002) Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 360(9334):678–682PubMedCrossRefGoogle Scholar
  69. 69.
    Titone L, Giommanco G, Giommanco GM (2003) Universal varicella vaccination program in Sicily. Varicella Vaccination in Europe. In: Proceedings of the 21st Annual Meeting of the European Society for Paediatric Infectious Diseases, Taormina, Sicily, April 2003Google Scholar
  70. 70.
    Wakefield AJ, Murch SH, Anthony A, Linnell J, Casson DM, Malik M, Berelowitz M, Dhillon AP, Thomson MA, Harvey P, Valentine A, Davies SE, Walker Smith JA (1998) Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351(9103):637–641PubMedCrossRefGoogle Scholar
  71. 71.
    Weibel RE, Neff BJ, Kuter BJ, Guess HA, Rothenberger CA, Fitzgerald AJ, Connor KA, McLean AA, Hilleman MR, Buynak EB (1984) Live attenuated varicella virus vaccine. Efficacy trial in healthy children. N Engl J Med 310(22):1409–1415PubMedCrossRefGoogle Scholar
  72. 72.
    Weibel RE, Kuter BJ, Neff BJ, Rothenberger CA, Fitzgerald AJ, Connor KA, Morton D, McLean AA, Scolnick EM (1985) Live Oka/Merck varicella vaccine in healthy children. Further clinical and laboratory assessment. JAMA 254(17):2435–2439PubMedCrossRefGoogle Scholar
  73. 73.
    Wise RP, Salive ME, Braun MM, Mootrey GT, Seward JF, Rider LG, Krause PR (2000) Postlicensure safety surveillance for varicella vaccine. JAMA 284(10):1271–1279PubMedCrossRefGoogle Scholar
  74. 74.
    Wutzler P, Farber I, Wagenpfeil S, Bisanz H, Tischer A (2001) Seroprevalence of varicella-zoster virus in the German population. Vaccine 20(1–2):121–124PubMedCrossRefGoogle Scholar
  75. 75.
    Yih WK, Brooks DR, Lett SM, Jumaan AO, Zhang Z, Clements KM, Seward JF (2005) The incidence of varicella and herpes zoster in Massachusetts as measured by the Behavioral Risk Factor Surveillance System (BRFSS) during a period of increasing varicella vaccine coverage, 1998–2003. BMC Public Health 5(1):68PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Nitu Sengupta
    • 1
    • 2
  • Robert Booy
    • 1
    • 3
  • H. J. Schmitt
    • 4
  • Heikki Peltola
    • 5
  • Pierre Van-Damme
    • 6
  • R. Fabian Schumacher
    • 7
  • Magda Campins
    • 8
  • Carlos Rodrigo
    • 9
  • Terho Heikkinen
    • 10
  • Jane Seward
    • 11
  • Aisha Jumaan
    • 11
  • Adam Finn
    • 12
  • Per Olcén
    • 13
  • Nancy Thiry
    • 6
  • Catherine Weil-Olivier
    • 14
  • Judith Breuer
    • 2
  1. 1.Centre for Child HealthRoyal London HospitalLondonUK
  2. 2.Centre for Infectious DiseasesQueen Mary School of Medicine and DentistryLondonUK
  3. 3.National Centre for Immunisation Research and SurveillanceWestmead Children’s HospitalSydneyAustralia
  4. 4.Zentrum für Präventive PädiatrieJohannes Gutenberg UniversitätMainzGermany
  5. 5.HUCH Hospital for Children and AdolescentsHelsinkiFinland
  6. 6.Centre for the Evaluation of Vaccination, Faculty of MedicineUniversity of AntwerpWilrijkBelgium
  7. 7.Clinica PediatricaUniversita’ degli Studi di BresciaBresciaItaly
  8. 8.Servicio de Medicina Preventiva y EpidemiologíaHospital Vall d’Hebron, Universitat Autònoma de BarcelonaBarcelonaSpain
  9. 9.Servicio de PediatríaHospital Universitario ‘Germans Trias I Pujol,’ Universitat Autònoma de BarcelonaBadalona (Barcelona)Spain
  10. 10.Department of PediatricsTurku University HospitalTurkuFinland
  11. 11.Center for Disease Control and Prevention, Division of Viral DiseasesNational Center for Immunization and Respiratory Diseases (proposed)AtlantaUSA
  12. 12.Institute of Child HealthUBHT Education CentreBristolUK
  13. 13.Department of Clinical Microbiology and ImmunologyÖrebro University HospitalÖrebroSweden
  14. 14.Hôspital Louis MourierColombresFrance

Personalised recommendations